Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Stemgent launches new self-replicative RNA reprogramming kit

Stemgent has launched its new Stemgent StemRNA-SR Reprogramming Kit, the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type.

This non-viral, non-DNA reprogramming kit combines self-replicative RNA (srRNA) and microRNA technology, providing stem cell researchers with a safe, flexible and cost-effective cellular reprogramming method applicable to both human fibroblasts and blood-derived endothelial progenitor cells (EPCs).

EPCs are uniquely genetically stable and can be efficiently established from fresh or cryopreserved human peripheral and cord blood. This latest innovation is being unveiled at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 24 – 27 in Stockholm, Sweden.

Stemgent chief executive officer Joseph Gentile said: "The combination of readily-available patient blood samples with integration-free RNA reprogramming technology supported by the Stemgent StemRNA-SR Reprogramming Kit and protocol is a great step forward for researchers developing clinically relevant iPS cell lines."